AstraZeneca's PD-L1 inhibitor Imfinzi has become the immunotherapy to be approved in the US for limited-stage small cell lung cancer (LS-SCLC), a particularly challenging form of the disease.
Imfinzi is also FDA-approved to treat non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), although its bladder cancer approval was withdrawn in the US last year after a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback